Opko Health, INC 8-K filings

OPKO Health has amended its Note Purchase Agreement to issue an additional $125 million in senior secured notes, maturing in 2044, backed by royalty interests.

OPKO Health reports Q2 2026 financial results, highlighting revenue growth and improved operating loss, alongside significant advancements in its drug development pipeline.

OPKO Health's 2026 Annual Meeting saw stockholders elect all eleven director nominees, approve the 2026 Equity Incentive Plan, and ratify the appointment of Ernst & Young LLP.

OPKO Health announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline including the initiation of a Phase 1 trial for MDX2301 and MDX2003, alongside a narrowed operating loss.

OPKO Health, Inc. announced the immediate appointment of Dr. Subbarao V. Uppaluri, a former CFO, to its Board of Directors, filling a vacancy.

OPKO Health announced a net loss of $31.3 million for Q4 2025 and a significant revenue decrease, despite advancing multiple pipeline programs and securing a major collaboration with Regeneron.

OPKO Health announced its third-quarter 2025 financial results, reporting a net income of $21.6 million and highlighting significant advancements in its biopharmaceutical pipeline and strategic partnerships.

OPKO Health, through its subsidiary BioReference Health, has completed the sale of its oncology and related clinical testing businesses to Labcorp for up to $225 million.

OPKO Health announced a significant increase in net loss for Q2 2025, driven by a non-recurring convertible note exchange expense, despite progress in its pharmaceutical pipeline and an expanded stock repurchase program.

OPKO Health, Inc. announced that its Compensation Committee approved significant stock option grants and cash bonuses for its named executive officers and other employees, effective May 27, 2025.

OPKO Health announces its first quarter 2025 financial results, featuring a definitive agreement to sell BioReference oncology assets to Labcorp and a collaboration with Entera Bio.

OPKO Health held its 2025 Annual Meeting of Stockholders, where all director nominees were elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was ratified as the independent accounting firm.

OPKO Health finalized exchange agreements to retire $159.2 million in convertible notes in exchange for common stock and cash.

OPKO Health, Inc. will exchange $152.5 million in convertible notes for common stock and cash with certain institutional holders.

Labcorp is set to acquire BioReference Health's oncology and oncology-related clinical testing services for up to $225 million, enhancing Labcorp's oncology leadership and expanding access to its services.

OPKO Health reports a slight increase in revenue and a return to net income profitability for Q4 2024, driven by strategic asset sales and cost-reduction initiatives.

OPKO Health's management team participated in investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, and provided presentation materials.

OPKO Health announced its third quarter 2024 financial results, including a significant gain from the sale of BioReference assets and the initiation of a $100 million share repurchase program.

OPKO Health finalized the sale of specific BioReference Health assets to Labcorp for $237.5 million, marking a strategic shift in their business focus.

OPKO Health reported its second quarter 2024 financial results, highlighted by a new share repurchase program, a $250 million note purchase agreement, and the sale of select BioReference assets.

OPKO Health's Compensation Committee approved restricted stock unit grants and bonus payments for its named executive officers.

OPKO Health has entered into a $250 million note purchase agreement with HealthCare Royalty, secured by profit share payments from Pfizer related to NGENLA.

OPKO Health reported its first quarter 2024 financial results, highlighted by a strategic agreement to sell select BioReference Health assets to Labcorp for $237.5 million.

OPKO Health's 2024 Annual Meeting saw stockholders elect all nominated directors, approve an increase in authorized shares, endorse executive compensation, and ratify the company's auditor.

OPKO Health has finalized the sale of its BioReference Health assets to Laboratory Corporation of America Holdings for a total of $237.5 million.

OPKO Health has agreed to sell certain assets of its BioReference laboratory testing business, excluding operations in New York and New Jersey, to Laboratory Corporation of America Holdings for approximately $237.5 million in cash.

OPKO Health announced its fourth quarter 2023 results, highlighting progress in its pharmaceutical pipeline and cost-cutting initiatives, while facing challenges in its diagnostics segment.

OPKO Health, Inc. announces that board member Alexis Borisy will not seek reelection at the company's 2024 Annual Meeting of Stockholders.

OPKO Health has terminated its share lending agreement with Jefferies Capital Services, recovering approximately 21.7 million shares to be held as treasury shares.